SNY - Sanofi
IEX Last Trade
48.49
-0.015 -0.031%
Share volume: 30,872
Last Updated: Thu 26 Dec 2024 08:29:55 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$48.50
-0.02
-0.03%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.21%
1 Month
0.02%
3 Months
-15.28%
6 Months
-0.08%
1 Year
-1.61%
2 Year
-0.47%
Key data
Stock price
$48.49
DAY RANGE
$48.07 - $48.75
52 WEEK RANGE
$45.71 - $58.97
52 WEEK CHANGE
-$2.21
DIVIDEND
$2.0369
EX-DIVIDEND DATE
05/09/2024
NEXT EARNINGS DATE
10/25/2024
Company detail
CEO: Paul Hudson
Region: US
Website: sanofi.com
Employees: 91,600
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sanofi.com
Employees: 91,600
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation.
Recent news